Nuclear factor erythroid-2-related factor 2 (Nrf2) is a stress-activated transcription factor regulating antioxidant genes, and a deficiency thereof, slowing lymphangiogenesis, has been reported in diabetic foot ulcer (DFU). The mode of Nrf2 regulation in DFU has been less explored. Emerging studies on miRNA-mediated target regulation show miRNA to be the leading player in the pathogenesis of the disease. In the present study, we demonstrated the role of miR-27b in regulating Nrf2-mediated angiogenesis in DFU. A lower expression of mRNA targets, such as Nrf2, HO-1, SDF-1α, and VEGF, was observed in tissue biopsied from chronic DFU subjects, which was in line with miR-27b, signifying a positive correlation with Nrf2. Similarly, we found significantly reduced expression of miR-27b and target mRNAs Nrf2, HO-1, SDF-1α, and VEGF in endothelial cells under a hyperglycemic microenvironment (HGM). To confirm the association of miR-27b on regulating Nrf2-mediated angiogenesis, we inhibited its expression through RNA interference-mediated knockdown and observed disturbances in angiogenic signaling with reduced endothelial cell migration. In addition, to explore the role of miR-27b and angiogenesis in the activation of Nrf2, we pretreated the endothelial cells with two well-known pharmacological compounds—pterostilbene and resveratrol. We observed that activation of Nrf2 through these compounds ameliorates impaired angiogenesis on HGM-induced endothelial cells. This study suggests a positive role of miR-27b in regulating Nrf2, which seems to be decreased in DFU and improves on treatment with pterostilbene and resveratrol.

Background: Extracellular vesicles (EVs) have emerged as promising cell-free therapeutic agents in regenerative medicine due to their ability to deliver bioactive molecules with enhanced stability and low immunogenicity. Their potential to replicate stem cell functions without the risks of live-cell transplantation has catalyzed a surge in global research. Objective: This study aims to perform a scientometric analysis of EV-based regenerative medicine research from 2014 to 2024, identifying publication trends, influential contributors, thematic clusters, and translational challenges. Methods: Data were retrieved from the Web of Science Core Collection and analyzed using CiteSpace software. The analysis included journal impact mapping, co-authorship networks, co-citation analysis, and thematic cluster identification. Metrics such as citation bursts, total link strength, and silhouette values were used to assess influence and thematic coherence. Results: The most prolific journals were Stem Cell Research & Therapy and International Journal of Molecular Sciences. China led in publication volume, while the USA dominated citation impact. Foundational works by Théry and Lai, including the MISEV guidelines, shaped methodological standards. Nine thematic clusters were identified, including oxidative stress, small EVs, mesenchymal stromal cells, muscle regeneration, and chronic kidney disease. A strategic shift toward engineered EVs and novel sources such as iPSCs and macrophages was evident. Key translational barriers include lack of standardization, scalability issues, and regulatory ambiguity. Conclusions: EV-based therapies are transitioning from foundational research to clinical application. Overcoming methodological and regulatory challenges will be critical to realizing their full therapeutic potential in regenerative medicine.

People are more susceptible to a variety of diseases based on their lifestyle and occupational patterns. Metabolic syndrome (MS) is a worldwide health issue that is linked to a variety of risk factors, including hyperglycemia, dyslipidemia, hypertension, and obesity. Herbal medicine has been used for a long time. Herbal medicines have emerged as a significant source and major focus for future drug development and human health care. Botanicals may be useful for treating or preventing metabolic syndrome because they often have a wide range of biologically active compounds that can work together to boost each other’s effectiveness or have a synergistic effect, giving more benefit than a single chemical substance. Some extracts of botanicals frequently contain natural active components that act on multiple biological targets, creating an opportunity to concurrently resolve multiple defects associated with metabolic syndrome. To find out if botanicals can be used to treat metabolic syndrome as a group, trials must be stratified to look at differences in disease severity, age, gender, and genetic variation in the sample populations.

Background and Objectives: In this current state, Type 2 Diabetes Mellitus (T2DM) is more prevalent in the population, and metformin is used as a first-line medication for treating it. There was up surge in the utilization of alternative therapies in the management of diabetes. Especially in diabetes, Herbal medicines are considered safe and reliable by majority of the population. Aim: The purpose of this research is aimed to estimate the safety and efficacy of Polyherbal Metabolite Compounds (PHMC) capsules in adults with T2DM. Materials and Methods: In this study, 60 T2DM patients aged 18-60 years were randomly assigned to Groups A (30) receiving Metformin 500 mg twice a day after food and Group B (30) receiving PHMC capsule 500 mg twice a day after food in a prospective, randomized and open-label clinical study. The in-silico simulation study was performed to selected plants major compounds on target protein Insulin-like Growth Factor-1 (1K3A). Result: The PHMC is found to be safe and effective in the management of T2DM. The FBS, PPBS and HbA1c were significantly lowered (p